Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 279

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 279
---
 | 3,561,546 |
| Former Chief Executive Officer and Director |     |      |      |     |        |         |     |        |         |     |        |           |     |              |           |    |     |           |           |
| Roger Sawhney(7)                            |     |      | 2024 |     |        | 187,917 |     |        | 108,397 |     |        | 1,301,500 |     |              |     6,833 | -8 |     |           | 1,604,647 |
| Former Chief Financial Officer              |     |      |      |     |        |         |     |        |         |     |        |           |     |              |           |    |     |           |           |
| Anna Eramo, M.D.                            |     |      | 2024 |     |        | 375,000 |     |        | 262,500 |     |        |   239,750 |     |              |    13,800 | -8 |     |           |   891,050 |
| Chief Medical Officer                       |     |      |      |     |        |         |     |        |         |     |        |           |     |              |           |    |     |           |           |

| (1) | Amounts reported in this column represent 2024 discretionary annual bonuses and, for Dr. Eramo only, an 
 additional $75,000 discretionary bonus paid in 2024.                                                    |

| (2) | Amounts reported in this column represent the aggregate grant date fair value of the stock options granted to                                                                                                                                         
 our named executive officers during 2024 under the 2023 Plan, as calculated in accordance with FASB ASC Topic 718. Assumptions used in the calculations of these amounts are included in Note 10 to our audited financial statements included in this 
 registration statement. The amounts do not reflect the actual economic value that may be realized by the named executive officer.                                                                                                                     |

| (3) | Commenced employment as our Chief Executive Officer in November 2024. |

| (4) | Amount shown represents a housing stipend. |

| (5) | Resigned as our Chief Executive Officer in connection with Ms. Turner’s appointment as Chief Executive 
 Officer.                                                                                               |

| (6) | Amount shown includes $13,800 in Company-paid